Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning
Primary Purpose
Myocardial Infarction
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Beta Blockers Carvedilol Phosphate
Sponsored by
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring remote ischemic conditioning, beta-blocker
Eligibility Criteria
Inclusion Criteria:
- Healthy male volunteer
- Not taking any medication
Exclusion Criteria:
- BMI < 18 kg/m2 or > 30 kg/m2
- Allergic history of any medication
- Baseline SBP > 150 mmHg or < 100 mmHg
- Baseline DBP > 100 mmHg or < 50 mmHg
- Strenuous exercise, excessive caffeine or alcohol, smoking 24 h prior to experiment
- Cannot undergoing remote ischemic conditioning for any reason
- Refuse to enroll
Sites / Locations
- Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Beta Blockers Carvedilol Phosphate
Control
Arm Description
Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning. Intervention: taking beta-blocker
Subjects are going to undergo remote ischemic conditioning without taking any drug.
Outcomes
Primary Outcome Measures
Changes in infarct size of rat heart perfused with human dialysate after taking beta-blocker or not to evaluate the effect of beta blocker on remote ischemic conditioning performed to healthy volunteers
Infarct size measurement after perfusing the rat heart with human serum-derived dialysate and comparison before and after remote ischemic conditioning performed to healthy volunteers
Secondary Outcome Measures
Full Information
NCT ID
NCT03169426
First Posted
May 16, 2017
Last Updated
February 19, 2018
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03169426
Brief Title
Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning
Official Title
Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
May 17, 2017 (Actual)
Primary Completion Date
November 10, 2017 (Actual)
Study Completion Date
November 10, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Remote ischemic conditioning has been shown to protect myocardium from ischemia-reperfusion injury during cardiac intervention or cardiac surgery. However, effect of beta-blocker, commonly used cardiovascular medication in patients with cardiac diseases such as hypertension or angina pectoris, on cardioprotective role of remote ischemic conditioning has not been well documented. The purpose of the study is to investigate the effect of beta-blocker on remote ischemic conditioning in healthy volunteers.
Detailed Description
This study is prospective cross-over study investigating effect of beta-blocker on cardioprotective role of remote ischemic conditioning. Eleven male healthy volunteers are going to take oral beta-blocker (carvedilol, 12.5 mg once) or not before undergoing remote ischemic conditioning (consisting of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion of upper arm), separated by 6-day wash-out period. To evaluate cardioprotective effect of remote ischemic conditioning, blood samples will be obtained before and after remote ischemic conditioning. Form the samples, human dialysate will be obtained and be perfused to rat heart through Langendorff apparatus before ischemia-reperfusion injury to the rat heart. Changes of infarct size of the rat heart will be compared between the beta-blocker and control groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction
Keywords
remote ischemic conditioning, beta-blocker
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Beta Blockers Carvedilol Phosphate
Arm Type
Experimental
Arm Description
Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.
Intervention: taking beta-blocker
Arm Title
Control
Arm Type
No Intervention
Arm Description
Subjects are going to undergo remote ischemic conditioning without taking any drug.
Intervention Type
Drug
Intervention Name(s)
Beta Blockers Carvedilol Phosphate
Intervention Description
Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
Primary Outcome Measure Information:
Title
Changes in infarct size of rat heart perfused with human dialysate after taking beta-blocker or not to evaluate the effect of beta blocker on remote ischemic conditioning performed to healthy volunteers
Description
Infarct size measurement after perfusing the rat heart with human serum-derived dialysate and comparison before and after remote ischemic conditioning performed to healthy volunteers
Time Frame
24 hour after remote ischemic conditioning to healthy volunteers
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male volunteer
Not taking any medication
Exclusion Criteria:
BMI < 18 kg/m2 or > 30 kg/m2
Allergic history of any medication
Baseline SBP > 150 mmHg or < 100 mmHg
Baseline DBP > 100 mmHg or < 50 mmHg
Strenuous exercise, excessive caffeine or alcohol, smoking 24 h prior to experiment
Cannot undergoing remote ischemic conditioning for any reason
Refuse to enroll
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yunseok Jeon, MD, PhD
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning
We'll reach out to this number within 24 hrs